Quarterly ResultJul 29, 2026, 07:10 AM
Anika Q2 Revenue $32.6M; Raises 2026 EBITDA Guidance
AI Summary
Anika Therapeutics reported strong second-quarter 2026 financial results, with total revenue increasing 16% to $32.6 million and record Commercial Channel revenue of $13.9 million. The company achieved a 65% gross margin and its highest Adjusted EBITDA since 2020 at $7.1 million. Based on this performance, Anika raised its full-year 2026 financial guidance, including a significant increase in its Adjusted EBITDA margin outlook to 13%-17%. The company also revised its 2027 revenue forecast to only include products with regulatory approval.
Key Highlights
- Q2 2026 Total Revenue: $32.6 million, up 16% year-over-year.
- Q2 2026 Commercial Channel Revenue: $13.9 million, a record high, up 17% year-over-year.
- Q2 2026 Gross Margin: 65%, expanded from 51% in the prior-year period.
- Q2 2026 Adjusted EBITDA: $7.1 million, highest since 2020.
- Full-year 2026 Adjusted EBITDA Margin Guidance raised to 13%-17% from 5%-10%.
- Full-year 2026 Total Revenue Growth Guidance raised to 5%-10% from 1%-9%.
- 2027 Commercial Channel Revenue Growth Guidance revised to 5%-15%.
Price Impact
More from ANIK